GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aurobindo Pharma Ltd (NSE:AUROPHARMA) » Definitions » Gross Profit

Aurobindo Pharma (NSE:AUROPHARMA) Gross Profit : ₹161,016 Mil (TTM As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Aurobindo Pharma Gross Profit?

Aurobindo Pharma's gross profit for the three months ended in Mar. 2024 was ₹44,310 Mil. Aurobindo Pharma's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was ₹161,016 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Aurobindo Pharma's gross profit for the three months ended in Mar. 2024 was ₹44,310 Mil. Aurobindo Pharma's Revenue for the three months ended in Mar. 2024 was ₹74,919 Mil. Therefore, Aurobindo Pharma's Gross Margin % for the quarter that ended in Mar. 2024 was 59.14%.

Aurobindo Pharma had a gross margin of 59.14% for the quarter that ended in Mar. 2024 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Aurobindo Pharma was 56.79%. The lowest was 51.48%. And the median was 53.92%.


Aurobindo Pharma Gross Profit Historical Data

The historical data trend for Aurobindo Pharma's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurobindo Pharma Gross Profit Chart

Aurobindo Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 124,255.10 139,468.60 125,513.70 133,238.70 161,016.00

Aurobindo Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34,477.00 36,359.30 39,139.70 41,206.60 44,310.40

Competitive Comparison of Aurobindo Pharma's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Aurobindo Pharma's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aurobindo Pharma's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aurobindo Pharma's Gross Profit distribution charts can be found below:

* The bar in red indicates where Aurobindo Pharma's Gross Profit falls into.



Aurobindo Pharma Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Aurobindo Pharma's Gross Profit for the fiscal year that ended in Mar. 2024 is calculated as

Gross Profit (A: Mar. 2024 )=Revenue - Cost of Goods Sold
=287045 - 126029
=161,016

Aurobindo Pharma's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=74919.2 - 30608.8
=44,310

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹161,016 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Aurobindo Pharma's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=44,310 / 74919.2
=59.14 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Aurobindo Pharma  (NSE:AUROPHARMA) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Aurobindo Pharma had a gross margin of 59.14% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Aurobindo Pharma Gross Profit Related Terms

Thank you for viewing the detailed overview of Aurobindo Pharma's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Aurobindo Pharma (NSE:AUROPHARMA) Business Description

Traded in Other Exchanges
Address
Plot No. 1, Survey No. 83/1, Galaxy, Floors: 22-24, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad, TG, IND, 500 032
Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. The company's product portfolio spans a variety of therapeutic areas. The vast majority of the company's sales are generated in the United States, followed by Europe. Most of Aurobindo's sales are derived from its formulations business, with the rest stemming from its active pharmaceutical ingredient operations. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Aurobindo Pharma (NSE:AUROPHARMA) Headlines

No Headlines